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Abstract
This study was carried out to evaluate the effects of probiotic supplementation on genetic and metabolic profiles in patients with
gestational diabetes mellitus (GDM) who were not on oral hypoglycemic agents. This randomized, double-blind, placebo-
controlled clinical trial was conducted in 48 patients with GDM. Participants were randomly divided into two groups to intake
either probiotic capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus
fermentum (2 × 109 CFU/g each) (n = 24) or placebo (n = 24) for 6 weeks. Probiotic intake upregulated peroxisome
proliferator-activated receptor gamma (P = 0.01), transforming growth factor beta (P = 0.002) and vascular endothelial growth
factor (P = 0.006), and downregulated gene expression of tumor necrosis factor alpha (P = 0.03) in peripheral blood mononuclear
cells of subjects with GDM. In addition, probiotic supplementation significantly decreased fasting plasma glucose (β, − 3.43 mg/
dL; 95% CI, − 6.48, − 0.38; P = 0.02), serum insulin levels (β, − 2.29 μIU/mL; 95% CI, − 3.60, − 0.99; P = 0.001), and insulin
resistance (β, − 0.67; 95% CI, − 1.05, − 0.29; P = 0.001) and significantly increased insulin sensitivity (β, 0.009; 95% CI, 0.004,
0.01; P = 0.001) compared with the placebo. Additionally, consuming probiotic significantly decreased triglycerides (P = 0.02),
VLDL-cholesterol (P = 0.02), and total-/HDL-cholesterol ratio (P = 0.006) and significantly increased HDL-cholesterol levels
(P = 0.03) compared with the placebo. Finally, probiotic administration led to a significant reduction in plasma malondialdehyde
(P < 0.001), and a significant elevation in plasma nitric oxide (P = 0.01) and total antioxidant capacity (P = 0.01) was observed
compared with the placebo. Overall, probiotic supplementation for 6 weeks to patients with GDM had beneficial effects on gene
expression related to insulin and inflammation, glycemic control, few lipid profiles, inflammatory markers, and oxidative stress.
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Introduction
Gestational diabetes mellitus is defined as impaired carbohy-
drate and lipid metabolism during pregnancy and is
characterized by progressive hyperglycemia and insulin resis-
tance and compensatory hyperinsulinemia [1]. In the USA, the
prevalence of gestational diabetes mellitus (GDM) was report-
ed up to 14% of pregnancies, accounting for 200,000 cases
annually [2]. The prevalence of this condition in Iran was
reported 4.7% [3]. Several studies have reported metabolic
and genetic disorders in women with GDM [4]. In a study
by Zhao et al. [5], it was seen the downregulation of peroxi-
some proliferator-activated receptor gamma (PPAR-γ) in pla-
centa that may predict hyperglycemia in offspring at young
adulthood. In addition, GDM is correlated with inflammatory
process and increased oxidative damage compared with nor-
mal pregnancy, which in turn are predictive of future type 2
diabetes mellitus [6] and cardiovascular disease (CVD) and
other atherosclerotic events [7].
It was documented that probiotic administration to preg-
nant women had favorable effects on metabolic profiles and
biomarkers of inflammation and oxidative stress. Few studies
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[8, 9] aimed to evaluate the impact of probiotic supplementa-
tion on metabolic profiles in patients with GDM and have
demonstrated that probiotic administration had beneficial ef-
fects on glycemic status, rather than lipid metabolism. In ad-
dition, Taylor et al. [10] reviewed the effects of probiotics on
metabolic outcomes in women with GDM. Consistently, it
was seen that improved glucose metabolism with a consider-
able decrease in homeostasis model of assessment-insulin re-
sistance (HOMA-IR) was observed following the supplemen-
tation of probiotic [10]. However, in a study conducted by
Lindsay et al. [11], there were no differences in metabolic
profiles or pregnancy outcomes in obese pregnant women that
may be due to the limited number of relevant studies. Taken
all together, the abovementioned studies have indicated that
probiotic administration during pregnancy has beneficial ef-
fects on metabolic outcomes in pregnant women such as pa-
tients with GDM and even healthy pregnant women.
However, data from studies investigating the effect of
probiotics on glycemic control, lipid profiles, biomarkers of
inflammation, and oxidative stress in patients with GDM are
inconclusive. The dose or CFU of a probiotic is an important
factor for the efficacy of probiotic supplementation on metabol-
ic profiles in pregnant women. It was documented that the dose
of more than 107 CFU probiotic counts could show beneficial
effects of probiotic supplementation on metabolic profiles in
pregnant women [12]. However, studies about specific doses
of probiotics are limited and further studies about optimal dose
of a probiotic supplementation in women with GDM are re-
quired. In addition, probiotic strains are also variable among
the studies, and it is difficult to evaluate the effects of a specific
probiotic species on metabolic profiles. Most studies have
widely used Lactobacillus and Bifidobacterium. Currently,
studies about the effects of specific probiotic strains are also
limited. There is no consensus on the specific dose of probiotics
and the ideal probiotic strains for the clinical intervention.
Therefore, further randomized controlled trial studies that fully
evaluate and compare the efficacy among variable CFU doses
and different probiotic strains are warranted, which are critically
important to determine the optimal dose and ideal probiotic
strain supplementation during pregnancy. In the current study,
we hypothesized that probiotic supplementation might affect
metabolic and genetic status of pregnant women with GDM.
This study was aimed to evaluate the effects of probiotic sup-
plementation on metabolic and genetic profiles in patients with
GDM who were not on oral hypoglycemic agents.
Methods
Trial Design and Participants
The current study, registered in the Iranian website for clinical
trials (http://www.irct.ir: IRCT20171010036697N1), was a
randomized, double-blind, placebo-controlled clinical trial.
This study was conducted in 48 patients with GDM at 24–
28 weeks of gestation referred to the Naghavi Clinic in
Kashan, Iran, between December 2017 and June 2018. The
investigation was performed in accordance with the
Declaration of Helsinki and informed consent was taken from
all participants. This study was approved by the ethics com-
mittee of Kashan University of Medical Sciences (KAUMS).
Eligible subjects were primigravida and aged 18–40 years (at
weeks 24–28 of gestation) who were diagnosed with GDM by
a Bone-step^ diagnosed based on the American Diabetes
Association guidelines [13]. Subjects with clinical character-
istics at enrollment including pre-eclampsia, eclampsia, thy-
roid disorders, smokers, those with kidney or liver diseases
and required commencing insulin therapy during intervention,
and taking probiotic products, including probiotic yogurt and
kefir during the intervention, were our exclusion criteria.
Study Design
To decrease potential confounding effects, random stratifica-
tion was used to assign participants to two test groups with
matching for BMI and age. Each test group was randomly
assigned to test the probiotic or placebo (n = 24 each group).
Patients were requested not to change their routine physical
activity or usual diets throughout the study and not to take any
anti-inflammatory and antioxidant medications or supple-
ments that might affect their nutritional status during the 6-
week intervention. Consumption of probiotic supplements
and placebos throughout the study was checked through ask-
ing subjects to return the medication containers. Furthermore,
a short message was sent to the cell phones of all patients
every day to remind participants to use the supplements. A
3-day food record (one weekend day and two weekdays) and
physical activity records were completed by all participants.
The individual’s nutrient intake was then calculated and aver-
aged at weeks 0, 3, and 6 of the intervention using Nutritionist
IV software (First Databank, San Bruno, CA) modified for
Iranian foods. Physical activity was described as metabolic
equivalents (METs) in hours per day. To determine the
METs for each participant, we multiplied the times (in hour
per day) reported for each physical activity by its related MET
coefficient by standard tables [14]. After diagnosis of GDM in
patients attending the center, they were first instructed about
the healthy diet; however, they were not given a specific menu
and they were just participating in a nutritional education class
that focused on basics of healthy diet.
Intervention
In the treatment group, patients received a probiotic capsule
containing Lactobacillus acidophilus, Lactobacillus casei,
Bifidobacterium bifidum, and Lactobacillus fermentum (2 ×
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109 CFU/g each) for 6 weeks. Probiotic supplements and pla-
cebos (corn starch) were produced by LactoCare®,
Zisttakhmir Company (Tehran, Iran), that is approved by the
Food and Drug Administration.
Assessment of Anthropometric Measures
A trained staff at the clinic took anthropometric measurements
at baseline and after the 12-week intervention. Body weight
was quantified after an overnight fast using a digital scale
(Seca, Hamburg, Germany).
Assessment of Outcomes
In the current study, we considered gene expression of
PPAR-γ as the primary outcome and other metabolic and
genetic profiles considered as secondary outcomes. Twenty-
milliliter fasting blood samples were collected at baseline and
6 weeks after the intervention at Kashan reference laboratory.
Then, the samples were stored at – 80 °C before analysis.
Serum insulin concentrations were quantified by the use of
an ELISA kit (DiaMetra, Milano, Italy) with inter- and intra-
assay coefficient variances (CVs) below 5%. HOMA-IR and
the quantitative insulin sensitivity check index (QUICKI)
were determined according to the standard formula [15].
Enzymatic kits (Pars Azmun, Tehran, Iran) were used to de-
termine fasting plasma glucose (FPG) and lipid profiles with
inter- and intra-assay CVs below 5%. Serum hs-CRP concen-
trations were determined by commercial ELISA kit (LDN,
Nordhorn, Germany) with inter- and intra-assay CVs below
7%. The plasma nitric oxide (NO) was determined using
Griess method [16], total antioxidant capacity (TAC) by the
method of ferric reducing antioxidant power developed by
Benzie and Strain [17], total glutathione (GSH) using the
method of Beutler et al. [18], and malondialdehyde (MDA)
concentrations were determined by the thiobarbituric acid re-
active substance spectrophotometric test [19] with inter- and
intra-assay CVs below 5%.
Isolation of Lymphocyte, RNA Extraction, and cDNA
Synthesis
Lymphocytes were isolated using 50%Percoll solution (Sigma-
Aldrich, Dorset, UK) gradient by centrifugation for 20 min and
3000 rpm at 4 °C [20]. Total RNAwas extracted based on acid
guanidinium-phenol-chloroform procedure using RNX™-plus
reagent (Cinnacolon, Tehran, Iran) according to the manufac-
turer’s instructions. RNA was treated with DNAse I
(Fermentas, Lithuania) for the elimination of any genomic
DNA contamination. Three micrograms of total RNAwas used
for cDNA synthesis with random hexamer and oligo (dT) 18
primers through RevertAid™ Reverse Transcriptase
(Fermantas, Canada) in total 20 μL reaction mixture [20].
Real-Time PCR Analysis
Appropriate primers for PPAR-γ, low-density lipoprotein recep-
tor (LDLR), interleukin-1 (IL-1), IL-8, tumor necrosis factor
alpha (TNF-α), transforming growth factor beta (TGF-β), vas-
cular endothelial growth factor (VEGF), and glyceraldehyde-3
phosphate dehydrogenase were designed (Table 1). Quantitative
real-time PCRwas performed by the LightCycler® 96 sequence
detection systems (Roche Diagnostics, Rotkreuz, Switzerland)
using 4 μL of 5× EvaGreen I Master Mix (Salise Biodyne,
Japan), 10 ng cDNA, and 200 nM of each forward and reverse
primers in a final volume of 20 μL.
Sample Size
In this study, we used a randomized clinical trial sample size
calculation formula where type one (α) and type two errors (β)
were 0.05 and 0.20 (power = 80%), respectively. According to
the previous trial [21], we used 0.15 as the SD and 0.13 as the
fold change in mean (d) of PPAR-γ as a primary outcome.
Based on the formula, we needed 20 subjects in each group;
after allowing for five dropouts in each group, the final sample
size was 25 persons in each group (Table 2).
Randomization
Randomization assignment was conducted using computer-
generated random numbers. Randomization and allocation
were hidden from the researchers and patients until the final
analyses were completed. The randomized allocation se-
quence, enrolling participants, and allocating them to inter-
ventions were carried out by a trained staff at the clinic.
Statistical Methods
The Kolmogorov-Smirnov test was done to determine the
normality of data. To detect the differences in anthropometric
parameters, dietary intakes and gene expression related to in-
sulin, lipid, and inflammation between treatment groups, we
used the independent-samples t test. Multiple linear regression
models were used to assess treatment effects on study out-
comes after adjusting for confounding variables, including
age and BMI. The effect sizes were presented as the mean
differences with 95% confidence intervals. P values < 0.05
were considered statistically significant. All statistical analy-
ses were done using the Statistical Package for Social Science
version 18 (SPSS Inc., Chicago, IL, USA).
Results
Among individuals in the probiotic group, one person due to
hospitalization was excluded (Fig. 1). The exclusion in the
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placebo group was also one participant due to placenta abrup-
tion. Finally, fourth-eight participants (24 in each group) com-
pleted the trial. The compliance rate in our study was high;
participants reported that more than 90% of probiotic and
placebo capsules were consumed during the course of the trial.
No side effects were reported following the intake of probiotic
in patients with GDM throughout the study.
Mean age, height, weight, and BMI at baseline as well as
mean weight and BMI after intervention were not statistically
different between the two groups (Table 2).
Based on the 3-day dietary records obtained throughout the
trial, we found no significant change in dietary macro- and
micro-nutrient intakes (data not shown).
After the 6-week intervention, probiotic supplementation
significantly decreased FPG (β, − 3.43 mg/dL; 95% CI, −
6.48, − 0.38; P = 0.02), serum insulin levels (β, − 2.29 μIU/
mL; 95% CI, − 3.60, − 0.99; P = 0.001), and HOMA-IR (β −
0.67; 95% CI, − 1.05, − 0.29; P = 0.001) and significantly
increased QUICKI (β, 0.009; 95% CI, 0.004, 0.01; P =
0.001) compared with the placebo (Table 3). Additionally,
consuming probiotic significantly decreased triglycerides (β,
− 19.17 mg/dL; 95% CI, − 35.86, − 2.48; P = 0.02), VLDL-
cholesterol (β, − 3.83 mg/dL; 95% CI, − 7.17, − 0.49; P =
0.02), and total-/HDL-cholesterol ratio (β, − 0.51; 95% CI,
− 0.86, − 0.15; P = 0.006) and significantly increased HDL-
cholesterol levels (β, 3.61; 95% CI, 0.31, 6.91; P = 0.03)
compared with the placebo. Finally, probiotic administration
led to a significant reduction in plasma MDA (β, −
0.63 μmol/L; 95% CI, − 0.80, − 0.47; P < 0.001) and a sig-
nificant elevation in plasma NO (β, 2.00 μmol/L; 95% CI,
0.34, 3.65; P = 0.01) and TAC (β, 49.99 mmol/L; 95% CI,
9.20, 90.79; P = 0.01) was observed compared with the pla-
cebo. Probiotic intake did not change other metabolic
parameters.
Table 1 Specific primers used for
real-time quantitative PCR Gene Primer Product
size (bp)
Annealing
temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-α F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
VEGF F: CTTCTGAGTTGCCCAGGAGA 216 54
R: CTCACACACACACAACCAGG
GAPDH glyceraldehyde-3-phosphate dehydrogenase, IL-1 interleukin-1, IL-8 interleukin-8, LDLR low-density
lipoprotein receptor, PPAR-γ peroxisome proliferator-activated receptor gamma, TNF-α tumor necrosis factor
alpha, TGF-β transforming growth factor beta, VEGF vascular endothelial growth factor
Table 2 General characteristics
of study participants Placebo group (n = 24) Probiotic group (n = 24) P
a
Age (year) 29.0 ± 4.2 28.8 ± 4.3 0.81
Height (cm) 161.2 ± 3.7 161.5 ± 3.1 0.76
Weight at study baseline (kg) 68.9 ± 7.3 68.0 ± 5.0 0.63
Weight at end-of-trial (kg) 70.8 ± 7.3 70.1 ± 5.2 0.67
Weight change (kg) 1.9 ± 0.5 2.1 ± 0.5 0.41
BMI at study baseline (kg/m2) 26.5 ± 2.7 26.1 ± 2.2 0.57
BMI at end-of-trial (kg/m2) 27.3 ± 2.7 26.9 ± 2.3 0.62
BMI change (kg/m2) 0.7 ± 0.2 0.8 ± 0.3 0.47
Data are means ± SDs
aObtained from independent t test
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Probiotic intake upregulated PPAR-γ (P = 0.01), TGF-β
(P = 0.002), and VEGF (P = 0.006) and downregulated gene
expression of TNF-α (P = 0.03) in peripheral blood
mononuclear cells of subjects with GDM (Figs. 2 and 3).
Probiotic supplementation did not affect gene expression of
LDLR, IL-1, and IL-8.
Table 3 Metabolic profiles, biomarkers of inflammation, and oxidative stress at baseline and after the 6-week intervention in patients with gestational
diabetes mellitus that received either probiotic supplements or placebo
Variables Placebo group (n = 24) Probiotic group (n = 24) Difference in outcome measures between
probiotic and placebo treatment groupsa
Baseline Week 6 Baseline Week 6 β (95% CI) Pb
FPG (mg/dL) 90.3 ± 6.9 91.3 ± 8.7 92.2 ± 11.2 89.2 ± 8.9 − 3.43 (− 6.48, − 0.38) 0.02
Insulin (μIU/mL) 11.8 ± 2.3 12.7 ± 3.8 12.0 ± 2.3 10.5 ± 2.3 − 2.29 (− 3.60, − 0.99) 0.001
HOMA-IR 2.6 ± 0.5 2.9 ± 1.1 2.7 ± 0.6 2.3 ± 0.5 − 0.67 (− 1.05, − 0.29) 0.001
QUICKI 0.33 ± 0.01 0.33 ± 0.01 0.32 ± 0.01 0.33 ± 0.009 0.009 (0.004, 0.01) 0.001
Triglycerides (mg/dL) 191.1 ± 66.6 208.2 ± 69.4 199.3 ± 51.8 196.5 ± 43.5 −19.17 (− 35.86, − 2.48) 0.02
VLDL-cholesterol (mg/dL) 38.2 ± 13.3 41.6 ± 13.9 39.9 ± 10.4 39.3 ± 8.7 − 3.83 (− 7.17, − 0.49) 0.02
Total cholesterol (mg/dL) 210.0 ± 40.0 214.0 ± 43.1 204.2 ± 41.9 201.7 ± 38.8 − 6.87 (− 16.05, 2.32) 0.13
LDL-cholesterol (mg/dL) 117.6 ± 30.1 120.7 ± 36.1 112.1 ± 38.1 108.2 ± 35.5 − 7.23 (− 17.06, 2.60) 0.14
HDL-cholesterol (mg/dL) 54.2 ± 6.0 51.7 ± 5.7 52.3 ± 11.3 54.2 ± 9.3 3.61 (0.31, 6.91) 0.03
Total-/HDL-cholesterol ratio 3.9 ± 0.8 4.2 ± 1.0 4.0 ± 1.0 3.8 ± 0.8 − 0.51 (− 0.86, 0.15) 0.006
NO (μmol/L) 30.7 ± 3.2 30.1 ± 3.0 30.9 ± 4.0 32.1 ± 4.7 2.00 (0.34, 3.65) 0.01
TAC (mmol/L) 716.4 ± 128.2 712.4 ± 113.1 710.6 ± 92.7 758.3 ± 93.7 49.99 (9.20, 90.79) 0.01
GSH (μmol/L) 584.9 ± 96.1 568.3 ± 98.3 627.1 ± 128.5 609.4 ± 98.4 35.71 (− 23.74, 95.16) 0.23
MDA (μmol/L) 3.0 ± 0.8 3.2 ± 0.7 2.8 ± 0.2 2.4 ± 0.2 − 0.63 (− 0.80, − 0.47) < 0.001
Data are mean ± SDs
FPG fasting plasma glucose, GSH total glutathione, HOMA-IR homeostasis model of assessment-insulin resistance, HDL-cholesterol high-density
lipoprotein-cholesterol, LDL-cholesterol low-density lipoprotein-cholesterol, MDA malondialdehyde, NO nitric oxide, QUICKI quantitative insulin
sensitivity check index, VLDL-cholesterol very low-density lipoprotein-cholesterol, TAC total antioxidant capacity
a BOutcome measures^ refers to the change in values of measures of interest between baseline and week 6. β [difference in the mean outcomes measures
between treatment groups (probiotic group = 1 and placebo group = 0)]
b Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age, and baseline BMI)
Randomized (n=50)
Allocated to placebo (n=25)
Lost to follow-up due to 
personal reasons (n=1)
Analyzed (n=24)
Allocated to intervention (n=25)
Lost to follow-up due to personal 
reasons (n=1)
Analyzed (n=24)
Assessed for eligibility (n=55)
Excluded (n=5) 
- Not meeting inclusion criteria (n=5) 
En
ro
llm
en
t
A
llo
ca
tio
n
Fo
llo
w
-u
p
A
na
ly
sis
Fig. 1 Summary of patient flow
diagram
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Discussion
In the current study, we investigated the effects of probiotic
supplementation on genetic and metabolic profiles in subjects
with GDM. We found that taking probiotic for 6 weeks by
patients with GDM had beneficial effects on gene expression
related to insulin and inflammation, glycemic control, few
lipid profiles, inflammatory markers, and oxidative stress.
Effects on Glycemic Control and Lipid Profiles
We found that taking probiotic supplements for 6 weeks by
patients with GDM led to a significant increase in gene expres-
sion of PPAR-γ, QUICKI, and HDL-cholesterol levels and a
significant reduction in FPG, insulin, HOMA-IR, triglycerides,
VLDL-cholesterol, total-/HDL-cholesterol but did not affect
gene expression of LDLR and other lipid profiles. However,
data on probiotic effects on gene expression related to insulin
and lipid metabolism are scarce; several studies have docu-
mented the beneficial effects of probiotic on glycemic control
and lipid profiles. We have previously shown that taking pro-
biotic supplements by patients with Parkinson’s disease for
12 weeks significantly increased gene expression of PPAR-γ
but did not affect gene expression of LDLR [22]. In another
study, Enterococcus faecium upregulated the mRNA expres-
sion of PPAR-γ in the spleen 3 and 7 days post-infection in
Escherichia coli O78-challenged broiler chickens [23].
Moreover, Lactobacillus reuteri I5007 could improve the gut
health of neonatal piglets through the increase in colonic bu-
tyric acid concentration and the upregulation of butyric acid,
PPAR-γ [24]. Also, probiotic L. casei significantly reduced
pro-inflammatory cytokines and hepatic inflammation through
modulating the toll-like receptor-mitogen-activated protein
kinase-PPAR-γ signaling pathways and intestinal microbiota
[25]. PPAR-γ plays key functions in the regulation of metab-
olism, including regulating insulin sensitivity, mitochondrial
biogenesis, carbohydrate and lipid homoeostasis, and tropho-
blast differentiation [26, 27]. Kuzmicki et al. [28] demonstrated
lower gene expression levels of PPAR-γ in women with GDM
rather than those with normal glucose tolerance. In another
study, polymorphisms in PPAR-γ were highly correlated with
GDM occurrence in pregnant women [29]. Therefore,
probiotics due to their beneficial actions on PPAR-γ may be
useful to control metabolic profiles in women with GDM. In
accordance with our study, results of a meta-analysis conduct-
ed in women with GDM demonstrated that probiotics
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Fig. 3 Change (means ± SDs) in gene expression levels of IL-1, IL-8,
TNF-α, TGF-β, and VEGF in women with GDMwho received probiotic
supplements and placebo. P value was obtained from independent t test.
N = 24 in each group. GDM, gestational diabetes mellitus; IL-1,
interleukin-1; IL-8, interleukin-8; LDLR, oxidized low-density
lipoprotein; PBMC, peripheral blood mononuclear cells; PPAR-γ,
peroxisome proliferator-activated receptor gamma; TNF-α, tumor
necrosis factor alpha; TGF-β, transforming growth factor beta; VEGF,
vascular endothelial growth factor
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improved glycemic control, triglycerides, and VLDL-
cholesterol levels [30]. In addition, in another meta-analysis
conducted by Taylor et al. [10], it was seen that probiotic sup-
plementation in women with GDMwas associated with a con-
siderable decrease in HOMA-IR. Dolatkhah et al. [8] observed
that taking probiotic supplements containing four strains
L. acidophilus LA-5, B. bifidum BB-12, Streptococcus
thermophilus STY-31, and Lactobacillus delbrueckii
bulgaricus LBY-27 by pregnant women for 6 weeks signifi-
cantly decreased insulin resistance. These results reinforce the
findings of Hyronimus et al. [31] who recommend probiotic
administration for at least 3 months. Insulin resistance in wom-
en with GDM results in inflammation, resulting in increased
inflammatory markers, such as C-reactive protein and fibrino-
gen [32]. On the other hand, the influence of gut microbiome
diversity improvement during pregnancy has been evaluated.
Pregnancies, type of delivery, gestation period (term/preterm),
and use of antiobiotics during pregnancy are all correlated with
the human microbial community composition [33].
Furthermore, the use of probiotics might help to regulate the
microbiota to promote beneficial metabolic activity, produce
favorable metabolites, and regulate the diversity of gut micro-
biota [34]. The beneficial effects of probiotics on glycemic
control and lipid profiles may be due to the increased produc-
tion of SCFA that increases GLP-1 secretion [35], modulating
the expression of lipogenic and glucogenic gene, including
PPAR-γ, glucose transporter type 4, and glucose-6-
phoshatase [36], and decreasing toll-like receptor activity,
which in turn reduces muscle insulin resistance [37].
Effects on Biomarkers of Inflammation and Oxidative
Stress
The present data showed that the consumption of probiotic by
patients with GDM significantly reduced gene expression of
TNF-α and significantly increased gene expression of TGF-β
and VEGF. In addition, probiotic supplementation to patients
with GDM caused a significant increase in NO and TAC, and a
significant reduction of MDA levels, but did not affect gene
expression of IL-1 and IL-8 and GSH levels. We have previ-
ously shown that taking probiotic containing L. acidophilus,
L. casei, and B. bifidum (2 × 109 CFU/g each) by women with
GDM for 6 weeks had beneficial effects on serum hs-CRP,
plasma TAC, and MDA levels. In another study, supplemen-
tation with Lactobacillus paracasei and L. reuteri in an animal
model decreased gene expressions of hepatic IL-1β, IL-6, and
TNF-α through inhibiting themitogen-activated protein kinase
and nuclear factor κB signaling pathways [38]. In addition, the
administration of L. casei and Enterococcus faecalis to an an-
imal model significantly reduced gene expression of TNF-α
and significantly increased gene expression of TGF-β in the
jejunum [39]. Probiotic administration for 12 weeks to patients
with multiple sclerosis significantly decreased gene expression
of IL-8 and TNF-α but did not influence gene expression of
IL-1 [21]. Furthermore, newborns receiving L. reuteri DSM
17938 for 1 month had a significant decrease in fecal pro-
inflammatory cytokines, IL-17, IL-8, and TNF-α and a signif-
icant increase in the fecal anti-inflammatory cytokine IL-10
[40]. Also, Lactobacillus rhamnosus GG significantly attenu-
ated pathogen-induced TNF-α mRNA expression in the hu-
man fetal gut [41]. However, in a meta-analysis, probiotic sup-
plementation to patients with rheumatoid arthritis did not affect
inflammatory parameters (TNF-α, IL-1β, IL-6, IL-10, and IL-
12) and oxidative stress indices (TAC and MDA) [42].
Increased inflammatory markers can increase the incidence
of maternal CVD in later life [43]. In addition, oxidative stress
and related toxic products can damage biological molecules,
which in turn enhance the susceptibility of offspring to chronic
disease [44, 45]. Therefore, probiotics due to their anti-
inflammatory and antioxidative actions may be useful to re-
duce complications related to metabolic disturbances in wom-
en with GDM. The upregulation of gene expression of
interleukin-18 by SCFA [46] and increased production of
methylketone family in the gut following the supplementation
of probiotic [47] might explain its anti-inflammatory and anti-
oxidant effects. Unfortunately, we did not evaluate SCFA
levels in the current study as a mechanism for the observed
effects but this might be explored in future studies.
This study had few limitations. In the current study, we did
not measure fecal bacteria loads before and after probiotic
supplementation. Due to funding limitations, we could not
assess gene expression related to oxidative stress.
Conclusions
Overall, probiotic supplementation for 6 weeks to patients
with GDM had beneficial effects on gene expression related
to insulin and inflammation, glycemic control, few lipid pro-
files, inflammatory markers, and oxidative stress. Our find-
ings suggest that probiotic supplementation may be relevant
valuable therapeutic agent for patients with GDM. Further
research is recommended to confirm the beneficial effects of
probiotic supplementation in other populations.
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